AI is finally breaking open cancer's most stubborn targets
Revolution Medicines just showed that a drug targeting the slippery RAS protein nearly doubled survival time in advanced pancreatic cancer patients, jumping from 6.6 to 13.2 months. Now, researchers are deploying AI to screen millions of molecules against notorious, smooth-surfaced culprits like p53 and MYC that fuel roughly 70 percent of cancers. What used to take decades of chemistry trial-and-error might soon become a solved computation problem.